

# ***Updated:* Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility**

**Effective June 17<sup>th</sup>, 2021**

Certain eligible pharmacies can administer publicly funded injectable COVID-19 vaccines to eligible Ontarians (see Pharmacy Eligibility below).

The purpose of this Executive Officer (EO) Notice (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**), the EO Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Billing**, and the accompanying Questions and Answers (Qs & As) documents, are to set out the terms and conditions for a participating pharmacy's submission of claims for payment (claims) for administering injectable COVID-19 vaccines to eligible Ontarians. Each document is a ministry policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators.

The two (2) EO Notices and the accompanying Qs & As documents are **not** intended to describe a pharmacy operator's obligations in respect of administering injectable COVID-19 vaccines under applicable legislation, other agreements with the Province of Ontario, or policies of the OCP. Pharmacy operators with questions about their legal obligations outside of the HNS Subscription Agreement should refer to the applicable legislation, other agreement, or OCP policy as appropriate.

This EO Notice (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**) replaces the previous EO notice on the same topic respecting the administration of publicly funded COVID-19 vaccines in Ontario pharmacies that was effective June 14<sup>th</sup>, 2021.

## **Pharmacy eligibility**

In order to be eligible to submit claims for administering a publicly funded COVID-19 vaccine, a pharmacy operator (also referred to in this document as a “participating pharmacy”) must be selected to participate by the ministry and meet the following requirements:

- Have a valid HNS Subscription Agreement with the ministry
- Have a valid agreement with the ministry respecting COVID-19 vaccine administration and the use of the Provincial COVID-19 vaccine solution (the “COVID-19 Vaccine Agreement”); and
- Enrolled in the 2020-21 Universal Influenza Immunization Program (UIIP).

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice.

## Patient eligibility

**Table 1 – Eligibility for first dose administration\***

Vaccine Product	Eligibility Criteria
Pfizer-BioNTech COVID-19 vaccine (DIN: 02509210)	Individuals who are 12 years of age or older at the time of vaccination
COVID-19 vaccine MODERNA (DIN: 02510014)	Individuals who are 18 years of age or older at the time of vaccination
COVISHIELD COVID-19 vaccine (DIN: 02512947) and COVID-19 vaccine AstraZeneca (PIN: 09857655)	Individuals who are 18 years of age or older at the time of vaccination and who have a confirmed allergy to components of the mRNA vaccines, if the individual has been assessed by an allergist / immunologist and the pharmacy has received a completed <a href="#">COVID-19 Vaccination: Allergy Form</a> prior to administering the COVISHIELD / AstraZeneca vaccine.

**Table 2 – Eligibility for second dose administration\*\***

Based on the National Advisory Committee on Immunization (NACI) recommendation<sup>1</sup>, the following rules apply to the interpretation of the eligibility criteria in Table 2 below.

- Persons who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated; and
- Persons who received a first dose of an mRNA vaccine (Pfizer-BioNTech or Moderna) should be offered the same mRNA vaccine for their second dose, unless the same mRNA vaccine is not readily available or the vaccine used for the first dose is unknown, in which case, another mRNA vaccine can be considered interchangeable and should be offered to complete the vaccine series. Note: An mRNA vaccine followed by a second AstraZeneca vaccine is not an acceptable interchangeable vaccine series.
- Where a different product is used to complete the mRNA vaccine series, the appropriate minimal dose interval should be determined from the product monograph of the mRNA vaccine used for the first dose (21 days where the Pfizer-BioNTech vaccine was used for the first dose, and 28 days where the Moderna vaccine was used for the first dose) <sup>2</sup>.

Vaccine Product	Eligibility Criteria
COVISHIELD COVID-19 vaccine (DIN: 02512947)  and	<ul style="list-style-type: none"> <li>• Individuals who received AstraZeneca/COVISHIELD vaccine for their first dose and choose to receive the AstraZeneca/COVISHIELD vaccine for their second dose may receive their second dose at least 8 weeks after their first dose, unless they are eligible for an earlier second dose based on the exception below.</li> <li>• Exception: individuals with certain health conditions as documented in a letter from a health care provider, as more</li> </ul>

<sup>1</sup> NACI [Rapid Response: Interchangeability of authorized COVID-19 vaccines](#) (PDF) and [Summary of the rapid response](#) (PDF) available online.

<sup>2</sup> For more information refer to the *COVID-19 Vaccine Series Second Dose Eligibility Quick Reference* located at this [link](#). Note that an interval of 28 days for Pfizer may be considered for operational feasibility.

<p>COVID-19 vaccine AstraZeneca (PIN: 09857655)</p>	<p>particularly described <a href="#">here</a>, may receive their second dose as early as 4 weeks</p> <hr/> <ul style="list-style-type: none"> <li>Individuals who received the Pfizer-BioNtech or Moderna mRNA vaccine for their first dose and had a severe allergic reaction or anaphylaxis to that vaccine, if at least 28 days have passed since their first dose, the individual has been assessed by an allergist / immunologist, and the pharmacy has received a completed <a href="#">COVID-19 Vaccination: Allergy Form</a> prior to administering the COVISHIELD / AstraZeneca vaccine.</li> </ul>
<p>Pfizer-BioNTech COVID-19 vaccine (DIN: 02509210)</p> <p>and</p> <p>COVID-19 vaccine MODERNA (DIN: 02510014)</p>	<ul style="list-style-type: none"> <li>Individuals who received their first dose of AstraZeneca/COVISHIELD vaccine and choose to receive one of the mRNA vaccines (Pfizer or Moderna) as their second dose may receive their second dose at least 8 weeks after their first dose, unless they are eligible for an earlier second dose based on the exception below.</li> <li>Exception: individuals with certain health conditions as documented in a letter from a health care provider, as more particularly described <a href="#">here</a>, may receive their second dose as early as 4 weeks.</li> </ul> <hr/> <ul style="list-style-type: none"> <li>Individuals who received their first dose of an mRNA vaccine (Pfizer or Moderna) may receive their second dose at an interval of up to 16 weeks, unless they are eligible for an earlier second dose, based on the schedule below.</li> </ul> <p><u>As of May 10, 2021:</u></p> <ul style="list-style-type: none"> <li>High-risk health care workers and individuals with certain health conditions, as more particularly described <a href="#">here</a>, as well as First Nations, Inuit and Métis individuals, if:</li> </ul>

	<ul style="list-style-type: none"> <li>▪ at least 21 days have passed<sup>3</sup> since their first dose with the Pfizer-BioNTech vaccine; or</li> <li>▪ at least 28 days have passed since their first dose with the Moderna vaccine.</li> </ul> <p><u>As of May 31, 2021:</u></p> <ul style="list-style-type: none"> <li>○ Individuals who are 80 years of age or older, if: <ul style="list-style-type: none"> <li>▪ at least 21 days have passed<sup>3</sup> since their first dose with the Pfizer-BioNTech vaccine; or</li> <li>▪ at least 28 days have passed since their first dose with the Moderna vaccine.</li> </ul> </li> </ul> <p><u>As of June 4, 2021:</u></p> <ul style="list-style-type: none"> <li>○ Individuals who are 70 years of age or older, if: <ul style="list-style-type: none"> <li>▪ at least 21 days have passed<sup>3</sup> since their first dose with the Pfizer-BioNTech vaccine; or</li> <li>▪ at least 28 days have passed since their first dose with the Moderna vaccine; or</li> </ul> </li> <li>○ Individuals who received their first dose on or before April 18, 2021.</li> </ul> <p><u>As of June 14, 2021:</u></p> <ul style="list-style-type: none"> <li>○ <a href="#">Individuals</a> who live in Halton, Peel, Porcupine, Toronto, Waterloo, Wellington-Dufferin-Guelph and York public health units, if they received their first dose of an mRNA vaccine on or before May 9, 2021. Only pharmacies in those public health units are eligible to submit claims for administering second doses to such individuals.</li> </ul>
--	--

<sup>3</sup> Note that an interval of 28 days for Pfizer may be considered for operational feasibility.

	<p><u>As of June 21, 2021:</u></p> <ul style="list-style-type: none"> <li>○ Individuals who received their first dose on or before May 9, 2021.</li> </ul> <p><u>As of June 23, 2021:</u></p> <ul style="list-style-type: none"> <li>○ <b>Individuals</b> who live in Durham, Halton, Hamilton, Peel, Porcupine, Simcoe-Muskoka, Toronto, Waterloo, Wellington-Dufferin-Guelph and York public health units, if they received their first dose of an mRNA vaccine on or before May 30<sup>th</sup>, 2021 and at least 28 days have passed since their first dose. Only pharmacies in those public health units are eligible to submit claims for administering second doses to such individuals.</li> </ul>
--	---

\* See Executive Officer Notice dated May 11, 2021 regarding the Ministry of Health’s direction to pause the administration of first doses of publicly funded AstraZeneca / COVISHIELD COVID-19 vaccines in Ontario pharmacies, available [here](#).

\*\*See the most recent version of the Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing for age restrictions for the vaccines based on the applicable product monographs, available [here](#).

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice and for details of the provincial rollout plan, please visit the [ministry’s website](#).

## Prior EO Notices

- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies, effective March 10, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective March 22, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective April 1, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective April 19, 2021.

- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective April 30, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 6, 2021.
- Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies (May 11, 2021)
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 13, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 18, 2021.
- Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies (May 21, 2021)
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 23, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 31, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective June 4, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective June 14, 2021.

**Additional Information:**

**For pharmacy billing:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

**For COVID-19 vaccine rollout in pharmacy:**

Please email the ministry at: [OPDPInfoBox@ontario.ca](mailto:OPDPInfoBox@ontario.ca)

**For Ministry COVID-19 Vaccine-Relevant Information and Planning Resources**

Please access this [website](#)

**For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.